FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
This Quarter Return
+33.27%
1 Year Return
-6.87%
3 Year Return
+443.49%
5 Year Return
+535.97%
10 Year Return
–
AUM
$134M
AUM Growth
+$134M
(+19%)
Cap. Flow
-$1.32M
Cap. Flow
% of AUM
-0.98%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
12
New
4
Increased
3
Reduced
–
Closed
2
Top Buys
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$7.49M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$6.93M |
| 3 |
FibroGen
FGEN
|
$5.45M |
| 4 |
Aclaris Therapeutics
ACRS
|
$1.76M |
| 5 |
Novavax
NVAX
|
$542K |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$19.5M |
| 2 |
Oric Pharmaceuticals
ORIC
|
$16.8M |
Sector Composition
| 1 | Healthcare | 90.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MYOK
1
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $54.4M | 40.54% | 399,360 | – | – |
|
2
Natera
NTRA
$23.1B
| $15.1M | 11.23% | 208,768 | – | – |
|
|
XLRN
3
DELISTED
Acceleron Pharma Inc.
XLRN
| $12.2M | 9.1% | 108,630 +66,600 | +158% | +$7.49M |
|
|
EPZM
4
DELISTED
Epizyme, Inc
EPZM
| $11.9M | 8.87% | 998,278 | – | – |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $11.9M | 8.85% | 1,641,804 +41,846 | +3% | +$303K |
|
|
6
FibroGen
FGEN
$47.8M
| $7.09M | 5.28% | 172,500 +132,500 | +331% | +$5.45M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $6.93M | 5.16% | +1,111,112 | New | +$6.93M |
|
|
8
Aclaris Therapeutics
ACRS
$209M
| $1.76M | 1.31% | +684,912 | New | +$1.76M |
|
|
9
Novavax
NVAX
$1.21B
| $542K | 0.4% | +5,000 | New | +$542K |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| – | – | -249,598 | Closed | -$19.5M |
|
|
11
Oric Pharmaceuticals
ORIC
$994M
| – | – | -496,893 | Closed | -$16.8M |
|